Longeveron licenses stem cell patent from University of Miami

Longeveron Inc. (NASDAQ: LGVN) announced it has licensed US Patent 12,168,028 B2 from the University of Miami for a stem cell technology targeting cardiovascular disease. The patent protects methods for deriving GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells.

The licensed technology addresses a significant safety concern in induced pluripotent stem cell therapy for heart conditions. Traditional methods of developing cardiomyocytes from induced pluripotent stem cells have caused malignant ventricular arrhythmias after transplantation into mammalian heart muscle, which has delayed clinical applications.

The patented method selects specific cells that become cardiomyocytes while eliminating cells with electrical automaticity found in conduction tissue. This approach aims to prevent dangerous heart rhythm abnormalities while allowing cells to engraft and contribute new contractile tissue.

"This technology provides a solution to one of the most difficult barriers to the implementation of induced pluripotent stem cells technology in the cardiovascular space," said Joshua Hare, Co-founder, Chief Science Officer, and Chairman at Longeveron.

The Miami-based biotechnology company develops regenerative medicines for life-threatening conditions. Its lead investigational product is laromestrocel, an allogeneic mesenchymal stem cell therapy currently being tested for hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty.

Longeveron stated the new technology may apply to various cardiovascular diseases in adults and rare pediatric diseases. The company recently received FDA approval for an investigational new drug application for pediatric dilated cardiomyopathy.

The information is based on a company press release statement.

You May Also Be Interested In

• TD Cowen Reiterates Buy Rating on argenx SE (ARGX)
• Nebius selects Komodor platform for Kubernetes reliability ops
• Spruce Power launches AI initiative to cut costs and improve service